Auris Medical Holding AG (NASDAQ:EARS) shares rose 2.5% on Friday . The stock traded as high as $4.53 and last traded at $4.48, with a volume of 71,810 shares trading hands. The stock had previously closed at $4.37.

EARS has been the topic of several recent analyst reports. Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, July 12th. Leerink Swann reissued a “buy” rating and set a $12.00 price target on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Finally, Jefferies Group reissued a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th.

The stock’s market cap is $146.93 million. The firm has a 50-day moving average of $4.06 and a 200 day moving average of $3.97.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.04. During the same quarter in the previous year, the company posted ($0.28) earnings per share. On average, equities research analysts anticipate that Auris Medical Holding AG will post ($1.01) earnings per share for the current year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.